

1.

Dominguez-Valentin M, Sampson JR, Seppala TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. *Genet Med*. July 2019. doi:[10.1038/s41436-019-0596-9](https://doi.org/10.1038/s41436-019-0596-9)

2.

Morak M, Schaefer K, Steinke-Lange V, et al. Full-length transcript amplification and sequencing as universal method to test mRNA integrity and biallelic expression in mismatch repair genes. *Eur J Hum Genet*. July 2019. doi:[10.1038/s41431-019-0472-8](https://doi.org/10.1038/s41431-019-0472-8)

3.

Seppala TT, Ahadova A, Dominguez-Valentin M, et al. Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. *Hered Cancer Clin Pract*. 2019;17:8. doi:[10.1186/s13053-019-0106-8](https://doi.org/10.1186/s13053-019-0106-8)

4.

Kayser K, Degenhardt F, Holzapfel S, et al. Copy number variation analysis and targeted NGS in 77 families with suspected Lynch syndrome reveals novel potential causative genes. *Int J Cancer*. 2018;143(11):2800-2813. doi:[10.1002/ijc.31725](https://doi.org/10.1002/ijc.31725)

5.

Engel C, Vasen HF, Seppala T, et al. No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. *Gastroenterology*. 2018;155(5):1400-1409.e2. doi:[10.1053/j.gastro.2018.07.030](https://doi.org/10.1053/j.gastro.2018.07.030)

6.

Moller P, Seppala TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. *Gut*. 2018;67(7):1306-1316. doi:[10.1136/gutjnl-2017-314057](https://doi.org/10.1136/gutjnl-2017-314057)

7.

Morak M, Ibisler A, Keller G, et al. Comprehensive analysis of the MLH1 promoter region in 480 patients with colorectal cancer and 1150 controls reveals new variants including one with a heritable constitutional MLH1 epimutation. *J Med Genet*. 2018;55(4):240-248. doi:[10.1136/jmedgenet-2017-104744](https://doi.org/10.1136/jmedgenet-2017-104744)

8.

Dominguez-Valentin M, Nakken S, Tubeuf H, et al. Identification of genetic variants for clinical management of familial colorectal tumors. *BMC Med Genet*. 2018;19(1):26. doi:[10.1186/s12881-018-0533-9](https://doi.org/10.1186/s12881-018-0533-9)

9.

Dominguez-Valentin M, Nakken S, Tubeuf H, et al. Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families. *Fam Cancer*. 2018;17(1):141-153. doi:[10.1007/s10689-017-0011-0](https://doi.org/10.1007/s10689-017-0011-0)

10.

Dominguez-Valentin M, Evans DGR, Nakken S, et al. Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds. *Hered Cancer Clin Pract.* 2018;16:4. doi:[10.1186/s13053-018-0086-0](https://doi.org/10.1186/s13053-018-0086-0)

11.

Vargas-Parra GM, Gonzalez-Acosta M, Thompson BA, et al. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis. *Int J Cancer.* 2017;141(7):1365-1380. doi:[10.1002/ijc.30820](https://doi.org/10.1002/ijc.30820)

12.

Morak M, Kasbauer S, Kerscher M, et al. Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6. *Fam Cancer.* 2017;16(4):491-500. doi:[10.1007/s10689-017-9975-z](https://doi.org/10.1007/s10689-017-9975-z)

13.

Moller P, Seppala T, Bernstein I, et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. *Gut.* 2017;66(9):1657-1664. doi:[10.1136/gutjnl-2016-311403](https://doi.org/10.1136/gutjnl-2016-311403)

14.

Moller P, Seppala T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut.* 2017;66(3):464-472. doi:[10.1136/gutjnl-2015-309675](https://doi.org/10.1136/gutjnl-2015-309675)

15.

Seppala T, Pylvanainen K, Evans DG, et al. Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. *Hered Cancer Clin Pract.* 2017;15:18. doi:[10.1186/s13053-017-0078-5](https://doi.org/10.1186/s13053-017-0078-5)

16.

Spier I, Holzapfel S, Altmuller J, et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. *Int J Cancer.* 2015;137(2):320-331. doi:[10.1002/ijc.29396](https://doi.org/10.1002/ijc.29396)

17.

Morak M, Heidenreich B, Keller G, et al. Biallelic MUTYH mutations can mimic Lynch syndrome. *Eur J Hum Genet.* 2014;22(11):1334-1337. doi:[10.1038/ejhg.2014.15](https://doi.org/10.1038/ejhg.2014.15)

18.

Steinke V, Holzapfel S, Loeffler M, et al. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families. *Int J Cancer.* 2014;135(1):69-77. doi:[10.1002/ijc.28650](https://doi.org/10.1002/ijc.28650)

19.

Thompson BA, Spurdle AB, Plazzer J-P, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. *Nat Genet.* 2014;46(2):107-115. doi:[10.1038/ng.2854](https://doi.org/10.1038/ng.2854)

20.

Spier I, Horpaopan S, Vogt S, et al. Deep intronic APC mutations explain a substantial proportion of patients with familial or early-onset adenomatous polyposis. *Hum Mutat.* 2012;33(7):1045-1050. doi:[10.1002/humu.22082](https://doi.org/10.1002/humu.22082)

21.

Tomsic J, Liyanarachchi S, Hampel H, et al. An American founder mutation in MLH1. *Int J Cancer.* 2012;130(9):2088-2095. doi:[10.1002/ijc.26233](https://doi.org/10.1002/ijc.26233)

22.

Morak M, Koehler U, Schackert HK, et al. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome. *J Med Genet.* 2011;48(8):513-519. doi:[10.1136/jmedgenet-2011-100050](https://doi.org/10.1136/jmedgenet-2011-100050)

23.

Hardt K, Heick SB, Betz B, et al. Missense variants in hMLH1 identified in patients from the German HNPCC consortium and functional studies. *Fam Cancer.* 2011;10(2):273-284. doi:[10.1007/s10689-011-9431-4](https://doi.org/10.1007/s10689-011-9431-4)

24.

Morak M, Massdorf T, Sykora H, Kerscher M, Holinski-Feder E. First evidence for digenic inheritance in hereditary colorectal cancer by mutations in the base excision repair genes. *Eur J Cancer.* 2011;47(7):1046-1055. doi:[10.1016/j.ejca.2010.11.016](https://doi.org/10.1016/j.ejca.2010.11.016)

25.

Kuiper RP, Vissers LELM, Venkatachalam R, et al. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. *Hum Mutat.* 2011;32(4):407-414. doi:[10.1002/humu.21446](https://doi.org/10.1002/humu.21446)

26.

Huhn S, Ingelfinger D, Bermejo JL, et al. Polymorphisms in CTNNB1 in relation to colorectal cancer with evolutionary implications. *Int J Mol Epidemiol Genet.* 2011;2(1):36-50.

27.

Kempers MJE, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. *Lancet Oncol.* 2011;12(1):49-55. doi:[10.1016/S1470-2045\(10\)70265-5](https://doi.org/10.1016/S1470-2045(10)70265-5)

28.

Carraï M, Steinke V, Vodicka P, et al. Association between TAS2R38 gene polymorphisms and colorectal cancer risk: a case-control study in two independent populations of Caucasian origin. *PLoS One.* 2011;6(6):e20464. doi:[10.1371/journal.pone.0020464](https://doi.org/10.1371/journal.pone.0020464)

29.

Campa D, Pardini B, Naccarati A, et al. Polymorphisms of genes coding for ghrelin and its receptor in relation to colorectal cancer risk: a two-step gene-wide case-control study. *BMC Gastroenterol.* 2010;10:112. doi:[10.1186/1471-230X-10-112](https://doi.org/10.1186/1471-230X-10-112)

30.

Lascorz J, Forsti A, Chen B, et al. Genome-wide association study for colorectal cancer identifies risk polymorphisms in German familial cases and implicates MAPK signalling pathways in disease susceptibility. *Carcinogenesis*. 2010;31(9):1612-1619. doi:[10.1093/carcin/bgq146](https://doi.org/10.1093/carcin/bgq146)

31.

Reuschenbach M, Kloor M, Morak M, et al. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. *Fam Cancer*. 2010;9(2):173-179. doi:[10.1007/s10689-009-9307-z](https://doi.org/10.1007/s10689-009-9307-z)

32.

Alston CL, Morak M, Reid C, et al. A novel mitochondrial MTND5 frameshift mutation causing isolated complex I deficiency, renal failure and myopathy. *Neuromuscul Disord*. 2010;20(2):131-135. doi:[10.1016/j.nmd.2009.10.010](https://doi.org/10.1016/j.nmd.2009.10.010)

33.

Bettstetter M, Dechant S, Ruummele P, et al. MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed and paraffin-embedded tissue samples. *Lab Invest*. 2008;88(12):1367-1375. doi:[10.1038/labinvest.2008.100](https://doi.org/10.1038/labinvest.2008.100)

34.

Frank B, Burwinkel B, Bermejo JL, et al. Ten recently identified associations between nsSNPs and colorectal cancer could not be replicated in German families. *Cancer Lett*. 2008;271(1):153-157. doi:[10.1016/j.canlet.2008.05.043](https://doi.org/10.1016/j.canlet.2008.05.043)

35.

Morak M, Laner A, Scholz M, Madorf T, Holinski-Feder E. Report on de-novo mutation in the MSH2 gene as a rare event in hereditary nonpolyposis colorectal cancer. *Eur J Gastroenterol Hepatol*. 2008;20(11):1101-1105. doi:[10.1097/MEG.0b013e328305e185](https://doi.org/10.1097/MEG.0b013e328305e185)

36.

Morak M, Schackert HK, Rahner N, et al. Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC. *Eur J Hum Genet*. 2008;16(7):804-811. doi:[10.1038/ejhg.2008.25](https://doi.org/10.1038/ejhg.2008.25)

37.

Steinke V, Rahner N, Morak M, et al. No association between MUTYH and MSH6 germline mutations in 64 HNPCC patients. *Eur J Hum Genet*. 2008;16(5):587-592. doi:[10.1038/ejhg.2008.26](https://doi.org/10.1038/ejhg.2008.26)